High FSTL3 expression is associated with high malignancy in colorectal, gastric, thyroid, NSCLC, and renal cell carcinoma, which suggest that FSTL3 may be a promising target in the clinical treatment of malignant tumors. Here, FSTL3 is linked to hereditary clear cell renal cell carcinoma.